Ensysce Regains Nasdaq Equity Compliance, Seeks Second Bid-Price Grace Period
ENSC sits 56% above its 52-week low of $0.23 on light trading volume (0.1× avg).
Summary
Ensysce Biosciences reported that its August 7 Series C financing restored Nasdaq equity compliance and that it has requested a second 180-day grace period to address the $1.00 bid price deficiency.
Key Events · Corporate Governance and Compliance · ENSC
-
Nasdaq Equity Rule Compliance Restored
The company believes it has a minimum of $2.5 million in stockholders' equity following the August 7, 2026 initial closing of its Series C financing, satisfying Nasdaq Listing Rule 5550(b)(1).
-
Second Bid-Price Grace Period Requested
With at least $5 million in stockholders' equity, the company believes it is eligible for a second 180-day grace period to regain compliance with the $1.00 bid price rule under Nasdaq Listing Rule 5550(a)(1). The formal request was submitted to Nasdaq on August 24, 2026.
-
Financing Milestone Still Pending
The second tranche of the Series C financing, which would bring total gross proceeds to approximately $43 million, remains contingent on achieving a clinical trial milestone that has not yet occurred.
-
Nasdaq Confirmation Awaited
The company awaits Nasdaq's formal confirmation regarding compliance with the Equity Rule and the response to its request for the second 180-day grace period.
Analysis · ENSC · Life Sciences
Ensysce Biosciences disclosed that the first tranche of its Series C financing, which closed August 7, 2026, restored its stockholders' equity above the $2.5 million minimum required for continued Nasdaq listing. The company also believes it now has at least $5 million in equity, making it eligible for a second 180-day grace period to regain compliance with the $1.00 bid price rule. The formal request was submitted to Nasdaq on August 24, 2026. This removes a near-term delisting overhang tied to the equity rule, though the bid price deficiency remains unresolved pending Nasdaq's confirmation.
How filings like this one have moved
In the 30 days to Aug 24, 2026, 29.4% of the 2796 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.03%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, ENSC was trading at $0.36 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $7M. The 52-week trading range was $0.23 to $2.75. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.